Currently Funded Cancer Research
The American Cancer Society has helped make possible almost every major cancer research breakthrough since 1946. Learn more about the Society’s substantial current spending on research here.
Related Articles
FDA Approves Toripalimab for Advanced Nasopharyngeal Cancer
Adding toripalimab (Loqtorzi) to chemo extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
BSH Abstract Submission | Haematology Abstracts
Submitting an abstract for BSH2023 will provide you with the opportunity to promote your research to a wide audience of haematology professionals.
Collection Details : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Prostate Cancer Patients Receiving ADT May Not Undergo Appropriate Monitoring – Oncology Nurse Advisor
More research is needed to address barriers to therapeutic monitoring of prostate cancer patients on androgen deprivation therapy, according to researchers.
FDA Broad Agency Announcement: Frequently Asked Questions for Oncology
FDA Broad Agency Announcement: Frequently Asked Questions for Oncology Researchers
National Cancer Plan – Join Us
The National Cancer Plan provides a comprehensive framework for meaningful collaboration to change how we know cancer today.
BRAF-Targeted Drug Approved for Pediatric Low-Grade Glioma
FDA has granted an accelerated approval to tovorafenib (Ojemda) for kids and teens who have low-grade glioma with changes in the BRAF gene.
Cancer Drug Access and Innovation Under the Inflation Reduction Act
This Viewpoint explores whether the Inflation Reduction Act’s provisions and price negotiations could affect investment in trials of new oncology therapies or indications.
Real-World Treatment Patterns and Economic Burden of Marginal Zone Lymphoma | Blood Cancers Today
A retrospective study analyzed treatment trends and associated health care costs for patients with MZL using Optum’s de-identified Clinformatics® Data Mart Database.
